<DOC>
	<DOCNO>NCT02492178</DOCNO>
	<brief_summary>The study aim describe pharmacokinetic property rectal artesunate well characterize severely ill patient use intravenous artesunate comparator .</brief_summary>
	<brief_title>Bio-availability Rectal Artesunate Children With Severe Falciparum Malaria</brief_title>
	<detailed_description>Individually randomize , open label , 2-arm , cross-over , clinical trial . Patients allocate receive rectal artesunate admission intravenous artesunate 12 hour intravenous artesunate admission rectal artesunate 12 hour . All patient treat severe malaria intravenous quinine . Frequent blood sample take fixed interval administration first second dose study drug . The time frame 24 hour thereafter patient continue standard antimalarial therapy .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>Weight ≥6 kilograms ≤ 34 kilogram Severe malaria ( WHO Guidelines 2013 ; Appendix 1 ) P. falciparum infection confirm Rapid Diagnostic Test ( P. falciparum monoinfection mixed infection P. ovale P. malariae ) Parents guardian sign Informed Consent Acute diarrhoea define &gt; 3 liquid stool previous 24 hour Visible anorectal malformation disease rectum Known hypersensitivity quinine artesunate A documented history effective dose parenteral antimalarial precede 24 hour single dose rectal artesunate previous 12 hour dose artemisinin base combination therapy previous 6 hour Comorbidity judgement investigator would interfere patient treatment result study place subject undue risk Participation another clinical trial earlier clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>